Show simple item record

dc.contributor.authorKaialy, Waseem
dc.contributor.authorNokhodchi, Ali
dc.date.accessioned2016-03-11T09:34:18Zen
dc.date.available2016-03-11T09:34:18Zen
dc.date.issued2016-01
dc.identifier.citationThe use of freeze-dried mannitol to enhance the in vitro aerosolization behaviour of budesonide from the Aerolizer® 2016, 288:291 Powder Technology
dc.identifier.issn00325910
dc.identifier.doi10.1016/j.powtec.2015.11.016
dc.identifier.urihttp://hdl.handle.net/2436/601156
dc.description.abstractThe efficiency of drug delivery from drug-carrier dry powder inhaler (DPI) systems is typically low. The purpose of this study was to examine the aerosolization performance of a hydrophobic drug, budesonide (BUD), from DPI formulations containing a promising carrier, freeze-dried mannitol (FDM), and to compare the results to those obtained previously with a hydrophilic drug, salbutamol sulphate (SS). The results showed that, in comparison to the formulation containing commercial BUD and commercial lactose, a total of 3.8-fold increase in the fine particle fraction (FPF) was obtained from the formulation containing FDM (FPF: 7.5% versus 29%) whereas a total of 4.6-fold increase in the FPF was obtained from the formulation containing FDM and leucine additive (FPF: 35%). Regression analysis showed DPI formulations containing carrier particles with a more elongated/less spherical shape, a higher content of fine particulates (< 5 μm) and a higher porosity to produce higher FPFs of BUD. FDM promoted the aerosolization of budesonide intended for pulmonary delivery. The addition of leucine (by 4.8%, w/w) has further improved the flow and the aerosolization properties of FDM. FDM produced higher aerodynamic diameters and smaller FPFs of BUD as compared to SS, attributable to BUD having a higher electrostatic charge density and a higher agglomeration tendency than SS.
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0032591015301595
dc.subjectDry powder inhalers
dc.subjectInhalations
dc.subjectInteractive mixtures
dc.subjectMannitol
dc.subjectPhysicochemical properties
dc.titleThe use of freeze-dried mannitol to enhance the in vitro aerosolization behaviour of budesonide from the Aerolizer®
dc.typeJournal article
dc.identifier.journalPowder Technology
html.description.abstractThe efficiency of drug delivery from drug-carrier dry powder inhaler (DPI) systems is typically low. The purpose of this study was to examine the aerosolization performance of a hydrophobic drug, budesonide (BUD), from DPI formulations containing a promising carrier, freeze-dried mannitol (FDM), and to compare the results to those obtained previously with a hydrophilic drug, salbutamol sulphate (SS). The results showed that, in comparison to the formulation containing commercial BUD and commercial lactose, a total of 3.8-fold increase in the fine particle fraction (FPF) was obtained from the formulation containing FDM (FPF: 7.5% versus 29%) whereas a total of 4.6-fold increase in the FPF was obtained from the formulation containing FDM and leucine additive (FPF: 35%). Regression analysis showed DPI formulations containing carrier particles with a more elongated/less spherical shape, a higher content of fine particulates (< 5 μm) and a higher porosity to produce higher FPFs of BUD. FDM promoted the aerosolization of budesonide intended for pulmonary delivery. The addition of leucine (by 4.8%, w/w) has further improved the flow and the aerosolization properties of FDM. FDM produced higher aerodynamic diameters and smaller FPFs of BUD as compared to SS, attributable to BUD having a higher electrostatic charge density and a higher agglomeration tendency than SS.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record